Freitag, 20. Oktober 2017


  • Pressemitteilung BoxID 496432

4SC hires experienced pharmaceutical manager and oncology expert

Martinsried, (lifePR) - 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, today announced that Dr Erich Enghofer has joined 4SC in June 2014 in the newly created position of Executive Vice President Oncology and Haematology thus further strengthening the company's expertise. The highly experienced pharma manager and oncology expert will primarily advance the strategic marketing of 4SC's main product resminostat in its further development toward market approval in the liver cancer indication. In this connection, Dr Enghofer will further strengthen 4SC's positioning and products vis-à-vis potential pharmaceutical partners, strategic and clinical opinion leaders and investors, and also support the company in its partnering activities in the field of business development.

Dr Enghofer has more than 30 years of experience in the pharmaceutical industry with a focus on oncology, during which he held various management and executive positions at Bayer, Medac Schering Onkologie, Amgen, Cyanamid-Lederle and Klinge Pharma (now Astellas). For the last nine years, he was head of the Business Unit Oncology (Haematology-Oncology since 2011) at Bayer HealthCare Deutschland in Leverkusen until May 2014. In this function, he was instrumental, among other things, in the attainment of market approval of the small molecule anti-cancer drug sorafenib (Nexavar(R)) in the liver cancer indication and the drug's market success in Germany. Dr Enghofer was a Board member of Deutsche Krebsgesellschaft (DKG, the German Cancer Society) until May 2014 and is a member of various high-profile professional organisations such as the German Association for Haematology and Oncology (DGHO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH) and the American Association for the Advancement of Science (AAAS).

Enno Spillner, CEO of 4SC AG, commented: "We are delighted to have Dr Erich Enghofer, an experienced pharmaceutical manager, joining 4SC. His vast expertise in the field of oncology, especially with the drug sorafenib for treating liver cancer, will further strengthen our team and is most welcome - especially for positioning our compound resminostat as a new potential liver cancer therapy and in our ongoing preparations for a Phase II trial in this indication. Dr Enghofer will also provide crucial support to 4SC in the expansion of a partner network to key opinion leaders and pharmaceutical companies, as well as in the business development process."

Dr Erich Enghofer commented: "I am very much looking forward to working in such a dynamic biotechnology company as 4SC, which has developed a promising and innovative approach for the liver cancer indication with resminostat. I have been following the company's activities and product developments, especially resminostat, for several years now. Liver cancer is the fifth most common type of cancer worldwide and the third most frequent tumour-related cause of death. The number of new cases has been rising sharply over the recent years, giving rise to a high unmet medical need. My goal is to make a contribution to attaining market approval for resminostat so as to make it available for patients as quickly as possible."

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

4SC AG

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 64 employees (55 FTEs) at 31 March 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Diese Pressemitteilungen könnten Sie auch interessieren

"Die Lehre Bruno-Grönings ist unärztlich und esoterisch"

, Gesundheit & Medizin, Landesärztekammer Hessen

„Hilfe und Heilung auf geistigem Weg“, verspricht der Bruno Gröning-Freundeskreis auf seiner Homepage. Angeblich „medizinisch nachweisbar“, soll...

"Zahncreme auf Spaghetti": Fachtagung zum Umgang mit Demenz

, Gesundheit & Medizin, Hochschule Osnabrück

In Deutschland leben heute 1,6 Millionen Menschen mit Demenz. Die Tendenz ist steigend. Damit wird auch der Bedarf an fachlicher Unterstützung...

Florida: 4000. Nieren-Transplantation in adventistischem Klinikverbund

, Gesundheit & Medizin, Freikirche der Siebenten-Tags-Adventisten in Deutschland / Süddeutscher Verband KdöR

Das Florida Hospital, ein Klinikverbund des Adventist Health Systems, welches zur Freikirche der Siebenten-Tags-Adventisten gehört, feierte Anfang...

Disclaimer